{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:49:44Z","timestamp":1761166184636,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["ZHYX202104"],"award-info":[{"award-number":["ZHYX202104"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.anndiagpath.2023.152165","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:09:02Z","timestamp":1684962542000},"page":"152165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Myc rearrangement and concurrent high protein expression of C-Myc\/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"66","author":[{"given":"Xingyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.anndiagpath.2023.152165_bb0005","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152165_bb0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152165_bb0015","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152165_bb0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.anndiagpath.2023.152165_bb0025","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152165_bb0030","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.anndiagpath.2023.152165_bb0035","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin\u2019s lymphoma study group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152165_bb0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2023.152165_bb0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.31557\/APJCP.2020.21.4.1103","article-title":"The frequency of double expresser in selected cases of high grade diffuse large B-cell lymphomas","volume":"21","author":"Naseem","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152165_bb0050","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.anndiagpath.2023.152165_bb0055","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.anndiagpath.2023.152165_bb0060","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.anndiagpath.2023.152165_bb0065","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","article-title":"Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL","volume":"127","author":"Savage","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152165_bb0070","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2018.195958","article-title":"MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients","volume":"104","author":"Ambrosio","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152165_bb0075","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2019.235556","article-title":"A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients","volume":"105","author":"Ziepert","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.anndiagpath.2023.152165_bb0080","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-21-2949","article-title":"Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC\/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma","volume":"28","author":"Xu-Monette","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.anndiagpath.2023.152165_bb0085","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152165_bb0090","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152165_bb0095","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/modpathol.2015.118","article-title":"Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"28","author":"Xu-Monette","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152165_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/PAS.0000000000000542","article-title":"High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis","volume":"40","author":"Li","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152165_bb0105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"25","key":"10.1016\/j.anndiagpath.2023.152165_bb0110","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.anndiagpath.2023.152165_bb0115","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas","volume":"16","author":"Sarkozy","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152165_bb0120","article-title":"Double-expressor phenotype (BCL-2\/c-MYC co-expression) of diffuse large B-cell lymphoma and its clinicopathological correlation","volume":"13","author":"Hashmi","year":"2021","journal-title":"Cureus"},{"issue":"28","key":"10.1016\/j.anndiagpath.2023.152165_bb0125","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.anndiagpath.2023.152165_bb0130","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152165_bb0135","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.anndiagpath.2023.152165_bb0140","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Horn","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.anndiagpath.2023.152165_bb0145","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.anndiagpath.2023.152165_bb0150","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:35:55Z","timestamp":1761078955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913423000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"alternative-id":["S1092913423000631"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152165","relation":{},"ISSN":["1092-9134"],"issn-type":[{"type":"print","value":"1092-9134"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myc rearrangement and concurrent high protein expression of C-Myc\/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152165"}}